BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models.

Journal: Cancer Cell

Published: 2019-05-13

DOI: 10.1016/j.ccell.2019.04.005

Affiliations: 17

Authors: 32

Go to article
Institutions FC
Department of Chemical Biology and Molecular Medicine (CBMM), MOFFITT, United States of America (USA) 0.22
Department of Cancer Biology, DFCI, United States of America (USA) 0.16
Malignant Hematology Program, MOFFITT, United States of America (USA) 0.09
Deaprtment of Hematopathology and Laboratory Medicine, MOFFITT, United States of America (USA) 0.08
Division of Hematology and Oncology, GW, United States of America (USA) 0.06
Department of Cancer Physiology, MOFFITT, United States of America (USA) 0.06
Department of Pathology and Microbiology, UNMC, United States of America (USA) 0.06
Department of Tumor Biology, MOFFITT, United States of America (USA) 0.03
UNC Department of Biochemistry and Biophysics, United States of America (USA) 0.03
UNC Lineberger Comprehensive Cancer Center, United States of America (USA) 0.03
Department of Molecular Oncology, MOFFITT, United States of America (USA) 0.03
Department of Hematology at the General Hospital, TMU, China 0.03
BayCare Laboratories, LLC, United States of America (USA) 0.03
Department of Biostatistics and Bioinformatics, MOFFITT, United States of America (USA) 0.03
National Cancer Center, CAMS & PUMC, China 0.02
Harvard Department of Biological Chemistry and Molecular Pharmacology (BCMP), United States of America (USA) 0.02
Harvard Department of Medicine, United States of America (USA) 0.02

Return